A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis

active non-infectious uveitis (intermediate uveitis, posterior uveitis, panuveitis)

Time to treatment failure on or after Period 1 Week 6 up to Period 1 Week 48

Proportion of participants meeting treatment failure criteria on or after Period 1 Week 6 up to Period 1 Week 24, Change in logarithm of the minimum angle of resolution (logMAR) best corrected visual acuity (BCVA) in each eye from best state achieved at or prior to Period 1 Week 6 up to Period 1 Week 24;, Change in central subfield thickness from best state achieved in each eye at or prior to Period 1 Week 6 up to Period 1 Week 24, Change in logMAR BCVA in each eye from best state achieved at or prior to Period 1 Week 6 up to Period 1 Week 48, Change in central subfield thickness from best state achieved in each eye at or prior to Period 1 Week 6 up to Period 1 Week 48

No related papers found yet.

Austria, Belgium, Czechia, Germany, Greece, Hungary, Italy, Poland, Spain